C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 201—LabelingSubpart D—Exemptions From Adequate Directions for Use

21 C.F.R. § 201.122 (2026)

Drugs for processing, repacking, or manufacturing

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1986–2011 14citing cases
At a glance

Courts have cited this section in 14 opinions since 1986.

A drug in a bulk package, except tablets, capsules, or other dosage unit forms, intended for processing, repacking, or use in the manufacture of another drug shall be exempt from section 502(f)(1) of the act if its label bears the statement “Caution: For manufacturing, processing, or repacking”; and if in substantially all dosage forms in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement “Rx only”, or if in substantially all dosage forms in which it may be dispensed it is subject to section 503(f)(1) of the act, the statement “Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian”. This exemption and the exemption under § 201.120 may be claimed for the same article. However, the exemption shall not apply to a substance intended for a use in manufacture, processing, or repacking which causes the finished article to be a new drug or new animal drug, unless:

(a) An approved new drug application or new animal drug application or a new animal drug index listing covers the production and delivery of the drug substance to the application or index listing holder by persons named in the application or in the request for determination of eligibility for indexing, and, for a new drug substance, the export of it by such persons under § 314.410 of this chapter; or

(b) If no application is approved with respect to such new drug or new animal drug, and it is not listed in the index, the label statement “Caution: For manufacturing, processing, or repacking” is immediately supplemented by the words “in the preparation of a new drug or new animal drug limited by Federal law to investigational use”, and the delivery is made for use only in the manufacture of such new drug or new animal drug limited to investigational use as provided in part 312 or § 511.1 or § 516.125 of this chapter; or

(c) A new drug application or new animal drug application or a request for addition to the index covering the use of the drug substance in the production and marketing of a finished drug product has been submitted but not yet approved, disapproved, granted, or denied, the bulk drug is not exported, and the finished drug product is not further distributed after it is manufactured until after the new drug application or new animal drug application is approved or the request for addition to the index is granted.

[41 FR 6911, Feb. 13, 1976, as amended at 41 FR 15844, Apr. 15, 1976; 50 FR 7492, Feb. 22, 1985; 55 FR 11576, Mar. 29, 1990; 57 FR 54301, Nov. 18, 1992; 67 FR 4906, Feb. 1, 2002; 72 FR 69119, Dec. 6, 2007]
The 14 cases that cite 21 C.F.R. § 201.122 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENWhite v. Weiner, 562 A.2d 378 (Pa. 1989).
cites § 201.122 5×cited by 25 cases
Where it cites § 201.122
“As directed 21 C.F.R. § 201.122 (1982) specifically exempts from labeling requirements.”
The case’s holding
State law claims for failure to warn are subject to the same policy of deference to the federal drug labeling scheme as federal misbranding claims.
Later courts cite it for
“our legislature unequivocally has expressed a policy of deference to the federal scheme in the area of drug labeling, and we can ascertain no reason not to extend that policy to civil cases raising misbranding claims.” · 2 citing courts
2
GREENUnited States v. Algon Chem. Inc., 879 F.2d 1154 (3d Cir. 1989).
cites § 201.122 4×cited by 15 cases
Where it cites § 201.122
“In an exercise of that authority, the FDA in 1952 promulgated a number of exemption provisions, including the predecessor of what is now 21 C.F.R. § 201.122 , which provides an exemption from the labeling requirements for the sale of bulk drugs.”
Later courts cite it for
“the fda's action effecting an increase in cost of drugs to practitioners does not undermine the practice of medicine or treatment decisions of veterinarians.” · 1 citing court
3
GREENMed. Ctr. Pharmacy v. Mukasey, 536 F.3d 383 (5th Cir. 2008).
cites § 201.122 1×cited by 34 cases
Where it cites § 201.122
“” An FDA regulation, 21 C.F.R. § 201.122 (2008), exempts from the misbranding requirement bulk drugs used to manufacture other animal drugs, so long as the finished product is not a unapproved "new drug.”
The case’s holding
Compounded drugs are new drugs under the FDCA but are exempt from approval only when they meet the specific statutory conditions for pharmacy compounding.
Later courts cite it for
“construing the fdca to give the fda authority over compounding would thus not necessarily 'lead to a result so bizarre that congress could not have intended it.” · 1 citing court
4
REDUnited States v. Algon Chem. Inc., 689 F. Supp. 394 (D.N.J. 1988).
cites § 201.122 10×cited by 2 cases
Reversed by United States v. Algon Chemical Inc., a Corporation, and Edward Latinsky, an Individual (1989): the Court of Appeals for the Third Circuit's own opinion in this case.
Where it cites § 201.122
“The defendant, Algon, argues that the 13 lots of drugs are exempt from the labeling requirements of § 352(f)(1) of the Act by virtue of an exempting regulation, 21 C.F. R. § 201.122. Additionally, defendant argues that the same exempting regulation serves to make § 321(w)(3)…”
5
GREENUnited States v. 9/1 KG Containers, 674 F. Supp. 1344 (C.D. Ill. 1987).
cites § 201.122 4×cited by 4 cases
Where it cites § 201.122
“21 C.F.R. § 201.122 (1987). It is the Government’s contention that the limitation on the exemption (“But the exemption shall not apply .”
6
GREENMed. Ctr. Pharmacy v. Gonzales, 451 F. Supp. 2d 854 (W.D. Tex. 2006).
cites § 201.122 2×cited by 5 cases
Where it cites § 201.122
“The regulation found at 21 C.F.R. § 201.122 exempts bulk ingredients from the Act’s adequate directions for use requirement unless the finished product is a new drug.”
Later courts cite it for
“implicitly exempt from the new drug approval process.” · 2 citing courts
7
GREENUnited States v. Articles of Drug, 634 F. Supp. 435 (N.D. Ill. 1986).
cites § 201.122 2×cited by 8 cases
Where it cites § 201.122
“The regulation which the Government for the first time cites as stating the firm order policy, 21 C.F.R. § 201.122 , is inapposite. That regulation merely states the conditions for exemption from labeling requirements; it does not embody the firm order/matching letter policy.”
Later courts cite it for
“create precise, objective limitations where none previously existed” · 1 citing court
8
GREENFisher v. Prof'l Compounding Centers of Am., Inc., 311 F. Supp. 2d 1008 (D. Nev. 2004).
cites § 201.122 1×cited by 8 cases
Where it cites § 201.122
“”); 21 C.F.R. § 201.122 (regulation exempting bulk suppliers from labeling requirements).”
9
GREENUnited States v. Franck's Lab, Inc., 816 F. Supp. 2d 1209 (M.D. Fla. 2011).
cites § 201.122 2×cited by 3 cases
Where it cites § 201.122
“Containers each addressed the enforceability of an FDA regulation that exempted bulk drug sales from the FDCA’s labeling requirements but limited the exemption to holders of new drug approval applications, thereby excluding veterinarians from the exemption.”
10
GREENUnited States v. 9/1 Kg. Containers, 854 F.2d 173 (7th Cir. 1988).
cites § 201.122 1×cited by 12 cases
Where it cites § 201.122
“21 C.F.R. § 201.122 . Schuyler’s bulk drugs do not qualify under this regulation as written, because although they are “intended for use in manufacture” (etc.”
11
GREENUnited States v. Undetermined Quantities of Articles of Drug, 145 F. Supp. 2d 692 (D. Md. 2001).
cites § 201.122 1×cited by 6 cases
Where it cites § 201.122
“See 21 C.F.R. § 201.122 . Therefore, for the above discussed reasons, the Court finds the Defendants’ products to be misbranded under § 352(f) of the FDCA.”
12
GREENBoswell v. Iowa Bd. of Veterinary Med., 477 N.W.2d 366 (Iowa 1991).
cites § 201.122 1×cited by 9 cases
Where it cites § 201.122
“section 352 (f) and 21 C.F.R. section 201.122 lawfully restrict the sale of bulk drugs that can be used to produce “new” drugs to firms that hold approved new animal drug permits.”
13
GREENUnited States v. Baxter Healthcare Corp., 712 F. Supp. 1352 (N.D. Ill. 1989).
cites § 201.122 1×cited by 7 cases
Where it cites § 201.122
“See also 21 C.F.R. § 201.122 (1988) (exempting drug repackaging operations from the labeling requirements of 21 U.”
Later courts cite it for
“baxter essentially asks this court to extend the bioequivalency exception - a mere suggestion in generix drug -to cover compounds that are equivalent to products resulting from fda-approved drugs.” · 1 citing court
14
GREENHegna v. EI Du Pont De Nemours & Co., 806 F. Supp. 822 (D. Minn. 1992).
cites § 201.122 1×cited by 4 cases
Where it cites § 201.122
“§ 353 (a) and 21 C.F.R. § 201.122 , [the bulk supplier] had no duty to provide a warning to [the drug manufacturer]”).”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198619982011

One bar per year. Tallest: 3 cases in 1989. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
N.D. Ill.23rd Cir.15th Cir.17th Cir.1M.D. Fla.1C.D. Ill.1Iowa1D. Md.1

The 8 courts with the most citing cases, of 13 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com